

Resource Summary Report

Generated by [NIF](#) on Sep 13, 2026

SK-LU-1

RRID:CVCL_0629

Type: Cell Line

Proper Citation

RRID:CVCL_0629

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0629

Proper Citation: RRID:CVCL_0629

Description: Cell line SK-LU-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung adenocarcinoma

Defining Citation: [PMID:833871](#), [PMID:1855224](#), [PMID:3518877](#), [PMID:6935474](#), [PMID:7017212](#), [PMID:9636188](#), [PMID:12068308](#), [PMID:12794755](#), [PMID:19935656](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:24135919](#), [PMID:26361996](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (CelloPub=CLPUB00712; PubMed=19935656)., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

AddexBio:C0016049/5014, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-57, BioSample:SAMN03472748, BioSample:SAMN10987792, cancercellines:CVCL_0629, CancerTools:161913, CCRID:1101HUM-PUMC000237, Cell_Model_Passport:SIDM01108, ChEMBL-Cells:ChEMBL3307447, ChEMBL-Targets:ChEMBL614913, CLS:300335, Cosmic:724877, Cosmic:909721, Cosmic:929967, Cosmic:932920, Cosmic:933576, Cosmic:1089218, Cosmic:1146944, Cosmic:1434960, Cosmic:1733129, Cosmic:1995631, Cosmic-CLP:909721, DepMap:ACH-000309, ECACC:93120835, EGA:EGAS00001000978, GDSC:909721, GEO:GSM385525, GEO:GSM385536, GEO:GSM434291, GEO:GSM513973, GEO:GSM514560, GEO:GSM784226, GEO:GSM794407, GEO:GSM827413, GEO:GSM887580, GEO:GSM888663, GEO:GSM1670434, IARC_TP53:121, ICLC:HTL96023, IGRhCellID:SK-LU-1%20GEO, IZSLER:BS TCL 81, KCLB:30057, LiGeA:CCLE_197, LINCS_LDP:LCL-1659, PharmacDB:SKLU1_1392_2019, PRIDE:PXD002556, PRIDE:PXD030304, Progenetix:CVCL_0629, PubChem_Cell_line:CVCL_0629, Wikidata:Q54953746

ID: CVCL_0629

Record Creation Time: 20220427T221545+0000

Record Last Update: 20260913T010042+0000

Ratings and Alerts

No rating or validation information has been found for SK-LU-1.

No alerts have been found for SK-LU-1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

Evaluations as SARS-CoV-2 Inhibitors and as Cytotoxic Agents. *Chemistry & biodiversity*, 23(3), e03702.

Li HS, et al. (2025) RANKL/PD-1 dual blockade demonstrates survival benefit for patients with advanced lung adenocarcinoma harboring KRAS mutations. *Cell reports. Medicine*, 6(7), 102235.

Kramer-Drauberg M, et al. (2025) Oncogenic mutant KRAS inhibition through oxidation at cysteine 118. *Molecular oncology*, 19(2), 311.

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. *Cell reports. Medicine*, 6(11), 102446.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. *International journal of cancer*, 154(6), 1029.

Sun F, et al. (2024) Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2. *eLife*, 12.

Hu H, et al. (2023) Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47. *The Journal of clinical investigation*, 133(2).

Nair NU, et al. (2023) A landscape of response to drug combinations in non-small cell lung cancer. *Nature communications*, 14(1), 3830.

Biswas S, et al. (2023) Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers. *Immunity*, 56(11), 2570.

Kreus MA, et al. (2023) High NHLRC2 expression is associated with shortened survival in lung adenocarcinoma. *Translational lung cancer research*, 12(6), 1221.

Yoo S, et al. (2022) Integrative network analysis of early-stage lung adenocarcinoma identifies aurora kinase inhibition as interceptor of invasion and progression. *Nature communications*, 13(1), 1592.

Zhou L, et al. (2022) EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer. *Journal of cancer research and clinical oncology*, 148(2), 309.

Li Y, et al. (2022) Long Noncoding RNA SNHG16 Regulates the Growth of Human Lung Cancer Cells by Modulating the Expression of Aldehyde Dehydrogenase 2 (ALDH2). *Journal of oncology*, 2022, 2411642.

Zhou X, et al. (2

Fang H, et al. (2022) miR-382-3p downregulation contributes to the carcinogenesis of lung adenocarcinoma by promoting AKT SUMOylation and phosphorylation. *Experimental and therapeutic medicine*, 24(1), 440.

Alessandrini I, et al. (2022) Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma. *Cancers*, 14(11).